Zobrazeno 1 - 10
of 649
pro vyhledávání: '"Shao, Zhimin"'
Despite significant advancements in robotic systems and surgical data science, ensuring safe and optimal execution in robot-assisted minimally invasive surgery (RMIS) remains a complex challenge. Current surgical error detection methods involve two p
Externí odkaz:
http://arxiv.org/abs/2406.19217
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 2, Pp 161-175 (2024)
Background and purpose: For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, trastuzumab treatment can prolong the overall survival and significantly improve the prognosis of patients. However, the refe
Externí odkaz:
https://doaj.org/article/48efb26de2c54ad4977ae3b73801824d
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 2, Pp 185-190 (2024)
Background and purpose: BRCA1/2 plays an important role in maintaining the genome stability. Whether BRCA1/2 germline mutation could increase the tumor sensitivity to radiotherapy, thereby inducing secondary primary cancer after radiotherapy is uncle
Externí odkaz:
https://doaj.org/article/be81482ef3ca4060a972b1960837904f
Autor:
Bu Hong, Fan Ying, Fan Zhaoqing, Hu Xichun, Li Man, Li Qiao, Liao Ning, Luo Ting, Nie Jianyun, Pan Yueyin, Qi Xiaowei, Shao Zhimin, Song Guohong, Sun Tao, Teng Yue-e, Tong Zhongsheng, Wang Jiayu, Wang Shusen, Wang Xue, Wang Yongsheng, Wang Zhonghua, Xu Binghe, Xu Ling, Xue Yan, Yang Wentao, Yao Herui, Ying Jianming, Yuan Peng, Zhang Jian, Zhang Qingyuan, Zhang Yongqiang, Zhao Jiuda
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 4, Pp 266-272 (2023)
Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immu
Externí odkaz:
https://doaj.org/article/256852e51361455da409e1403a8b21fa
Autor:
Ni, Jiahui, Shao, Zhimin, Zhang, Zhongzhou, Hou, Mingzheng, Zhou, Jiliu, Fang, Leyuan, Zhang, Yi
Pansharpening in remote sensing image aims at acquiring a high-resolution multispectral (HRMS) image directly by fusing a low-resolution multispectral (LRMS) image with a panchromatic (PAN) image. The main concern is how to effectively combine the ri
Externí odkaz:
http://arxiv.org/abs/2111.12483
Publikováno v:
In Information Fusion March 2024 103
Publikováno v:
Zhongguo aizheng zazhi, Vol 33, Iss 6, Pp 551-559 (2023)
Sentinel lymph node biopsy (SLNB) is a surgical technique for diagnosing and treating purposes in breast cancer, which is one of the major advances with milestone significance in the field of breast surgery. As a less-invasive axillary surgery, the d
Externí odkaz:
https://doaj.org/article/b19cc08d5d884e1b92e8ebbcb30e1fad
Current status and focus of breast reconstruction research in China and abroad: a bibliometric study
Autor:
REN Hengyu, HAO Shuang, CHEN Jiajian, YANG Benlong, CAO Ayong, LIU Guangyu, SHAO Zhimin, WU Jiong
Publikováno v:
Zhongguo aizheng zazhi, Vol 33, Iss 6, Pp 581-588 (2023)
Background and purpose: According to the 2020 global cancer burden data of the International Agency for Research on Cancer (IARC), breast cancer has replaced lung cancer as the most common type of cancer worldwide. The aim of this study was to conduc
Externí odkaz:
https://doaj.org/article/e079f05b24cc48f9b23c1b06be0e7625
Autor:
Yu, Sanjian, Qiu, Xia, Wang, Zezhou, Xiao, Jialong, Ji, Hui, Shan, Hailin, Shao, Qing, Xia, Heng, Cao, Feng, Li, Jun, Fu, Cuixia, Chen, Liqin, Lu, Xiaofang, Su, Tingting, Yu, Qianqian, Hou, Shengqun, Wang, Honglian, Zheng, Ying, Shao, Zhimin, Liu, Yun, Hu, Zhen
Publikováno v:
In Cancer Pathogenesis and Therapy April 2024
Publikováno v:
Zhongguo aizheng zazhi, Vol 33, Iss 2, Pp 95-102 (2023)
According to the data released by the International Cancer Research Institute of the World Health Organization (WHO), breast cancer is the malignant tumor with the highest incidence rate in women, and seriously endangers women's health.Many impressiv
Externí odkaz:
https://doaj.org/article/13f3a6b7b6724251830a858856aa803a